OPG Slams Dutch drug Price Reduction

6 August 1995

Dutch pharmacist-owned wholesale cooperative OPG has attacked Health Minister Els Borst's plan to cut drug prices in the New Year by 15%-20% in order to establish maximum prices in line with average levels elsewhere in Europe. OPG's special reserve fund, created in anticipation of a drastic change in the market, has reduced forecast net profits for 1994-5 from 65.5 million guilders to 30.1 million guilders ($19.4 million).

The legislation will affect drugmakers as well as wholesalers, since it will be based on the prices at which pharmacies buy in their stocks. OPG believes this will affect about 70% of consolidated sales, worth 1.5 billion guilders out of gross trading volume of 1.7 billion guilders, and says job losses cannot be ruled out.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight